Uniseed

Uniseed is Australia's longest-running venture capital fund, established in 2000, with a strong focus on commercializing innovative research from its partner universities and research institutions. These include leading institutions like the University of Queensland, the University of Melbourne, and Monash University, among others. Uniseed supports startups in various sectors such as biotechnology, quantum computing, pharmaceuticals, and green energy. As a seed-stage investor, Uniseed helps researchers turn their ideas into marketable products by offering seed capital, expert guidance, and access to an extensive network of industry professionals. The firm has overseen more than 60 startups and over 12 successful exits, including notable deals like the sale of Spinifex Pharmaceuticals to Novartis and Fibrotech to Shire. In partnership with UniSuper, Uniseed manages significant capital to support deep-tech startups aiming for global impact. Uniseed’s latest $75 million commitment ensures its continued support for emerging technologies, and with its growing network of academic and institutional partners, the fund is poised to lead more groundbreaking innovations to market.